- Trxade
Group Inc. is an expanding healthcare tech platform builder that aims to
assist small, community-based pharmaceutical businesses and the patients
who comprise their customers through drug pricing and delivery operations
as well as telemedicine consultations
- Trxade
Group recently announced its year-end financial statement for 2019, noting
revenues had grown nearly double over the previous year, from $3.83
million to $7.43 million
- The
company is celebrating a decade in operation with four platforms that are
integrated synergistically to serve the needs of rural and
neighborhood-centric health businesses on a subscription basis
- Trxade’s
telehealth services enable patients to access licensed medical
professionals from virtually anywhere via personal technology for minor
health needs, ensuring them that during a time of pandemic they won’t need
to risk unnecessary exposure to the COVID-19 virus at facilities treating
other patients
- Trxade
recently announced its uplisting to the Nasdaq Capital Market and rang the
exchange’s opening bell as part of its efforts to continue building its
financial resources
Before the pandemic sweep of the novel coronavirus (or
COVID-19) began causing alarm among health policy advisers and care providers,
leading to restrictions on movement for the general population,
forward-thinking health services provider Trxade Group Inc. (NASDAQ: MEDS) was building a
synergistic set of operational platforms to help expand the reach of care
providers to underserved communities via online “telemedicine” technology and
medicinal delivery services that now seem prescient in their nature.
Amid Trxade Group’s efforts to expand its platforms, the
company saw continued revenue growth that culminated in its recent uplisting to
the Nasdaq Capital Market and an announcement that it expected gross proceeds
of $5.2 million from a public offering’s sale of common stock (http://ibn.fm/N1kFG).
On March 30, Trxade announced its year-end financials,
reporting that annual revenues from continuing operations grew from $3.83
million in 2018 to practically double that amount in 2019 at $7.43 million. The
company also saw operating income rise from a loss of ($87,616) in 2018 to a
gain of $125,244 (http://ibn.fm/1N4TM).
The improved financial picture reflects Trxade’s efforts to
make healthcare services affordable and accessible across all 50 states
coincidental to price transparency mechanisms and increased profit margins for
buyers and sellers of pharmaceuticals.
As the company completes its first decade of operations, it
has grown to enfold four platforms that are integrated to best serve the needs
of rural and neighborhood-centric health businesses. The platforms are the
company’s trademarked trading platform that serves 12,100 registered
pharmacies, a licensed virtual (online) wholesaler, web-based telehealth
services through the company’s Bonum Health subsidiary and the company’s
DelivMeds same-day/mail order pharmaceuticals delivery service.
“In addition to increased revenue growth from our companies,
Trxade Group achieved a number of significant milestones around innovation and
enhancements in 2019 that add even more value to our role as a strategic
provider to independent pharmacies and lower cost healthcare to all consumers,”
Board Chairman and CEO Suren Ajjarapu stated in a news release. “We believe our
platform will become even more important for our customers in the years to
come. We have a clear vision of our strategy and the opportunities ahead and
look forward to another successful year of growth.”
The company’s report states it added 3,266 new independent
pharmacies to its trading platform in 2019 and saw a 23.07 percent rise in
pharmacy purchasers during the year, as well as an 8.86 percent increase in
purchases per pharmacy on the trading platform.
On March 10, Trxade announced (http://ibn.fm/kH95J) that it was
launching a new service through Bonum and DelivMeds to provide subscribers with
three premium medical teleconferencing visits and free prescription delivery
through company subsidiaries each month under the standard membership rate,
freeing patients from unnecessary exposure to viral illnesses such as COVID-19
or the seasonal flu and RSV at hospitals and urgent care facilities when
consulting for “clinical needs and minor visits that do not require
conventional appointments.”
The telehealth services can provide patients with private
access to board-certified physicians from virtually anywhere, using the patients’
personal communication technology.
For more information, visit the company’s website at www.TrxadeGroup.com
NOTE TO INVESTORS: The latest news and updates
relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
